Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | ADAMTS5 | Q9UNA0 | 17/20 | 0.47 |
| ▸ | ADAM17 | P78536 | 7/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 4/20 | 0.42 |
| ▸ | MMP13 | P45452 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29874400 | 1.00 | CYP3A4 (0.52) | CYP3A4ADAMTS5ADAM17NAMPTADAMTS4 | |
| SCHEMBL29873860 | 0.86 | MMP13 (0.43) | CYP3A4ADAMTS5ADAM17ADAMTS4MMP2 | |
| SCHEMBL23367190 | 0.86 | MMP13 (0.43) | CYP3A4ADAMTS5ADAM17ADAMTS4MMP2 | |
| SCHEMBL23354903 | 0.83 | CYP3A4 (0.63) | CYP3A4ADAMTS5ADAM17MMP2MMP13 | |
| SCHEMBL10200290 | 0.81 | IDO1 (0.41) | CYP3A4ADAMTS5ADAM17NAMPTADAMTS4 | |
| SCHEMBL24927817 | 0.81 | ADAM17 (0.41) | CYP3A4ADAMTS5ADAM17NAMPTADAMTS4 | |
| SCHEMBL29978673 | 0.81 | ADAM17 (0.41) | CYP3A4ADAMTS5ADAM17NAMPTADAMTS4 | |
| SCHEMBL29835186 | 0.81 | ADAMTS5 (0.56) | CYP3A4ADAMTS5ADAM17ADAMTS4MMP2 | |
| SCHEMBL19709386 | 0.81 | ADAMTS5 (0.56) | CYP3A4ADAMTS5ADAM17ADAMTS4MMP2 | |
| SCHEMBL29979092 | 0.80 | ADAMTS7 (0.36) | CYP3A4ADAMTS5ADAM17NAMPTADAMTS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027985-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027985-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | ADAMTS7, MMP7, ADAMTS1 | CYP3A4 3940/4885ADAMTS5 4/4885ADAM17 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.